scholarly journals Effect of Timing of Fungicide Applications on Development of Rusts on Daylily, Geranium, and Sunflower

Plant Disease ◽  
2004 ◽  
Vol 88 (6) ◽  
pp. 657-661 ◽  
Author(s):  
D. S. Mueller ◽  
S. N. Jeffers ◽  
J. W. Buck
Keyword(s):  
Disease Management ◽  
Effective Means ◽  
Management Program ◽  
Integrated Disease Management ◽  
Lesion Development ◽  
Application Timing ◽  
Fungicide Efficacy ◽  
Ornamental Crops ◽  
Rust Pathogens ◽  
Over Time

Integrated disease management should provide the most effective means of controlling rusts on ornamental crops over time, and fungicides are an important component of an integrated rust management program. Proper timing of fungicide applications is critical for effective disease management; however, information about application timing is lacking for rusts on ornamental crops. The objective of this study was to determine how fungicides affected rust development on daylily, geranium, and sunflower plants when applied several days before or after inoculation. Five fungicides registered for use against rusts on ornamental crops were evaluated: the strobilurin azoxystrobin; three sterol biosynthesis inhibiting fungicides—myclobutanil, propiconazole, and triadimefon; and the broad spectrum protectant chlorothalonil. All five fungicides significantly reduced lesion development by rust pathogens on daylily, geranium, and sunflower plants when these compounds were applied preventatively up to 15 days before inoculation and infection with a few exceptions (e.g., propiconazole on geranium and triadimefon on sunflower). Curative activity, which resulted from fungicide application after inoculation, was observed for the three rusts with some products (azoxystrobin on all three plants and myclobutanil, propiconazole, and triadimefon on geranium) when applied up to 7 days postinoculation. In general, fungicide efficacy with several of the products decreased as the time from application to inoculation (preventative activity) or inoculation to application (curative activity) increased.

scholarly journals Night Spraying Peanut Fungicides I. Extended Fungicide Residual and Integrated Disease Management

Plant Disease ◽  
2010 ◽  
Vol 94 (6) ◽  
pp. 676-682 ◽  
Author(s):  
J. Augusto ◽  
T. B. Brenneman ◽  
A. K. Culbreath ◽  
P. Sumner
Keyword(s):  
Disease Management ◽  
Chemical Control ◽  
Sclerotium Rolfsii ◽  
Residual Activity ◽  
Field Trials ◽  
Stem Rot ◽  
Integrated Disease Management ◽  
Cercospora Arachidicola ◽  
Puccinia Arachidis ◽  
Fungicide Efficacy

The efficacy of chemical control of stem rot (caused by Sclerotium rolfsii) of peanut (Arachis hypogaea) relies partially on increasing deposition and residual activity in the lower canopy. Tebuconazole (0.21 kg a.i./ha, four applications) and azoxystrobin (0.31 kg a.i./ha, two applications) were each applied on peanut plants in daylight or at night, when leaves were folded, in two Tifton, GA, field trials in 2007. Both timings of each fungicide provided similar control of early leaf spot (caused by Cercospora arachidicola). Night applications of azoxystrobin and tebuconazole reduced stem rot at digging and increased yield compared with day applications. Night applications of tebuconazole were also tested in Nicaragua from 2005 to 2007. Peanut plants had less stem rot, similar levels of rust (caused by Puccinia arachidis), and higher yield with night applications than with day applications. Residual activity of azoxystrobin and tebuconazole were improved on the bottom shaded leaves (on which fungicides would be better deposited with night application) compared with top, sun-exposed leaves (where most fungicide would be deposited with a day application) according to a bioassay with S. rolfsii. Increased fungicide residual activity within the bottom canopy may increase fungicide efficacy on stem rot and augment peanut yield.

scholarly journals Impact of an integrated disease management program in reducing exacerbations in patients with severe asthma and COPD

2014 ◽  
Vol 108 (12) ◽  
pp. 1794-1800 ◽  
Author(s):  
Vipul V. Jain ◽  
Richard Allison ◽  
Sandra J. Beck ◽  
Ratnali Jain ◽  
Paul K. Mills ◽  
...  
Keyword(s):  
Disease Management ◽  
Severe Asthma ◽  
Disease Management Program ◽  
Management Program ◽  
Integrated Disease Management

scholarly journals Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study

2019 ◽  
Author(s):  
Eline Meijer ◽  
Annelies E. van Eeden ◽  
Annemarije L. Kruis ◽  
Melinde R.S. Boland ◽  
W. J.J. (Pim) Assendelft ◽  
...  
Keyword(s):  
Primary Care ◽  
Disease Management ◽  
Usual Care ◽  
Clinical Improvement ◽  
Chronic Obstructive ◽  
Integrated Disease Management ◽  
Copd Patients ◽  
Treatment Type ◽  
Post Hoc ◽  
Over Time

Abstract Background: The cluster randomized controlled trial on (cost-)effectiveness of integrated chronic obstructive pulmonary disease (COPD) management in primary care (RECODE) showed that integrated disease management (IDM) in primary care had no effect on quality of life (QOL) in COPD patients compared with usual care. It is possible that only a subset of COPD patients in primary care benefit from IDM. We therefore examined which patients benefit from IDM, and whether patient characteristics predict clinical improvement over time. Method: Post-hoc analyses of the RECODE trial among 1086 COPD patients. Logistic regression analyses were performed with baseline characteristics as predictors to examine determinants of improvement in QOL, defined as a minimal decline in Clinical COPD Questionnaire (CCQ) of 0.4 points after 12 and 24 months of IDM. We also performed moderation analyses to examine whether predictors of clinical improvement differed between IDM and usual care. Results: Regardless of treatment type, more severe dyspnea (MRC) was the most important predictor of clinically improved QOL at 12 and 24 months, suggesting that these patients have most room for improvement. Although the interaction effect between gender and treatment condition was nonsignificant, it appeared that male patients were worse off with IDM than usual care. Conclusions: More severe dyspnea is a key predictor of improved QOL in COPD patients over time. Future IDM programs, provided that they are effective, may benefit from tailoring to gender such that the programs meet the individual needs of both female and male COPD patients. Trial registration: Netherlands Trial Register, NTR2268. Registered 31 March 2010, https://www.trialregister.nl/trial/2144 .

scholarly journals Impact of a Post-Discharge Integrated Disease Management Program on COPD Hospital Readmissions

2017 ◽  
Vol 62 (11) ◽  
pp. 1396-1402 ◽  
Author(s):  
Ashlee N Russo ◽  
Gayathri Sathiyamoorthy ◽  
Chris Lau ◽  
Didem Saygin ◽  
Xiaozhen Han ◽  
...  
Keyword(s):  
Disease Management ◽  
Disease Management Program ◽  
Hospital Readmissions ◽  
Management Program ◽  
Integrated Disease Management ◽  
Post Discharge

scholarly journals Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study

2020 ◽  
Author(s):  
Eline Meijer ◽  
Annelies E. van Eeden ◽  
Annemarije L. Kruis ◽  
Melinde R.S. Boland ◽  
W. J.J. (Pim) Assendelft ◽  
...  
Keyword(s):  
Primary Care ◽  
Disease Management ◽  
Usual Care ◽  
Clinical Improvement ◽  
Patient Characteristics ◽  
Integrated Disease Management ◽  
Copd Patients ◽  
Treatment Type ◽  
Post Hoc ◽  
Over Time

Abstract Background: The cluster randomized controlled trial on (cost-)effectiveness of integrated chronic obstructive pulmonary disease (COPD) management in primary care (RECODE) showed that integrated disease management (IDM) in primary care had no effect on quality of life (QOL) in COPD patients compared with usual care (guideline-supported non-programmatic care). It is possible that only a subset of COPD patients in primary care benefit from IDM. We therefore examined which patients benefit from IDM, and whether patient characteristics predict clinical improvement over time.Method: Post-hoc analyses of the RECODE trial among 1086 COPD patients. Logistic regression analyses were performed with baseline characteristics as predictors to examine determinants of improvement in QOL, defined as a minimal decline in Clinical COPD Questionnaire (CCQ) of 0.4 points after 12 and 24 months of IDM. We also performed moderation analyses to examine whether predictors of clinical improvement differed between IDM and usual care.Results: Regardless of treatment type, more severe dyspnea (MRC) was the most important predictor of clinically improved QOL at 12 and 24 months, suggesting that these patients have most room for improvement. Clinical improvement with IDM was associated with female gender (12-months) and being younger (24-months), and improvement with usual care was associated with having a depression (24-months).Conclusions: More severe dyspnea is a key predictor of improved QOL in COPD patients over time. More research is needed to replicate patient characteristics associated with clinical improvement with IDM, such that IDM programs can be offered to patients that benefit the most, and can potentially be adjusted to meet the needs of other patient groups as well.Trial registration: Netherlands Trial Register, NTR2268. Registered 31 March 2010, https://www.trialregister.nl/trial/2144.

scholarly journals Integrated Disease Management of Tomato Late Blight

2014 ◽  
Vol 8 ◽  
pp. 67-76 ◽  
Author(s):  
Krishna K. Shrestha ◽  
Richard Ashley
Keyword(s):  
Disease Management ◽  
Late Blight ◽  
Disease Incidence ◽  
Trichoderma Viride ◽  
Integrated Disease Management ◽  
Artemisia Vulgaris ◽  
The Past ◽  
The World ◽  
Serious Disease ◽  
Over Time

Tomato late blight caused by Phytophthora infestans (Mont.) de Bary is a  serious disease of tomato and potato worldwide. The disease causes severe  crop losses in the tomato growing regions of the world. Most of the cultivars  grown in the world are reported to be susceptible to late blight. Systemic  fungicides have been used widely in the past, but the disease has developed  resistance over time. The present study was carried out to minimize  fungicide use through integrated pest management. The bio-pesticides  Azadirachta indica (Neem), Artemisia vulgaris (Mugwort) and Trichoderma  viride were tested along with the fungicides Krilaxyl (metalaxyl 8% and  mancozeb 64%) and Dithane M-45 (mancozeb 80%) in Nepal during 2000  and 2001. All three bio-pesticides were found more effective than the control  in reducing development of the disease and they increased yield over the  control by 17 to 41%. However, the fungicides, Krilaxyl and Dithane M-45  were observed even more effective. Two transplanting dates ie first and third  week of July were tested against late blight in rainy season during 2000and  2001 and observed its effect on yields. Lower disease incidence and better  yield were found in the second planting.  Nepal Agric. Res. J. Vol. 8, 2007, pp. 67-76DOI: http://dx.doi.org/10.3126/narj.v8i0.11583

scholarly journals Disease Control for Florida Tomatoes

EDIS ◽  
2013 ◽  
Vol 2013 (6) ◽  
Author(s):  
Mathews Paret ◽  
Ken Pernezny ◽  
Pam Roberts
Keyword(s):  
Plant Pathology ◽  
Disease Management ◽  
Disease Control ◽  
Environmental Conditions ◽  
Disease Management Program ◽  
Management Program ◽  
Plant Diseases ◽  
Integrated Disease Management ◽  
Tomato Production ◽  
Successful Approach

Successful disease management has always been vital in Florida tomato production, given the generally ideal environmental conditions for most plant diseases. An integrated disease management program is a successful approach. This 7-page fact sheet was written by Mathews Paret, Ken Pernezny, and Pam Roberts, and published by the UF Department of Plant Pathology, June 2013. http://edis.ifas.ufl.edu/vh056

scholarly journals Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study

2020 ◽  
Author(s):  
Eline Meijer ◽  
Annelies E. van Eeden ◽  
Annemarije L. Kruis ◽  
Melinde R.S. Boland ◽  
W. J.J. (Pim) Assendelft ◽  
...  
Keyword(s):  
Primary Care ◽  
Disease Management ◽  
Usual Care ◽  
Clinical Improvement ◽  
Patient Characteristics ◽  
Integrated Disease Management ◽  
Copd Patients ◽  
Treatment Type ◽  
Post Hoc ◽  
Over Time

Abstract Background: The cluster randomized controlled trial on (cost-)effectiveness of integrated chronic obstructive pulmonary disease (COPD) management in primary care (RECODE) showed that integrated disease management (IDM) in primary care had no effect on quality of life (QOL) in COPD patients compared with usual care (guideline-supported non-programmatic care). It is possible that only a subset of COPD patients in primary care benefit from IDM. We therefore examined which patients benefit from IDM, and whether patient characteristics predict clinical improvement over time.Method: Post-hoc analyses of the RECODE trial among 1086 COPD patients. Logistic regression analyses were performed with baseline characteristics as predictors to examine determinants of improvement in QOL, defined as a minimal decline in Clinical COPD Questionnaire (CCQ) of 0.4 points after 12 and 24 months of IDM. We also performed moderation analyses to examine whether predictors of clinical improvement differed between IDM and usual care.Results: Regardless of treatment type, more severe dyspnea (MRC) was the most important predictor of clinically improved QOL at 12 and 24 months, suggesting that these patients have most room for improvement. Clinical improvement with IDM was associated with female gender (12-months) and being younger (24-months), and improvement with usual care was associated with having a depression (24-months).Conclusions: More severe dyspnea is a key predictor of improved QOL in COPD patients over time. More research is needed to replicate patient characteristics associated with clinical improvement with IDM, such that IDM programs can be offered to patients that benefit the most, and can potentially be adjusted to meet the needs of other patient groups as well.Trial registration: Netherlands Trial Register, NTR2268. Registered 31 March 2010, https://www.trialregister.nl/trial/2144.

Sign in / Sign up

Export Citation Format

Share Document